HBIO 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위

03

가격 $8.34

시가총액 (MRQ) $38M

P/E (TTM) -5.6

EPS (TTM) $-1.50

매출 (TTM) $88M

ROE (TTM) -89.9%

부채/자본 (MRQ) 4.9

52주 범위 $0–$8

HBIO 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의

04

범위

막대

막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.

주식 분할 2

배당락일	분할	유형
2026년 3월 16일	1-for-10	역방향
2013년 11월 4일	1319-for-1000	정방향

Harvard Bioscience, Inc. - Common Stock 정보 위키백과 회사 개요

05 · wikidata

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

History

Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.

The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.

In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.

From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.

In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.

The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.

In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).

In 2015 the company acquired HEKA Electronik of Germany.

In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.

In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.

James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.

For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.

In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.

In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.

Products

Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.

Finance

The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.

In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.

더 보기 접기

출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗

Wikidata ↗

섹터Healthcare 산업Life Sciences Tools & Services 직원316 국가US

10년 성과 매출, 순이익, 마진 및 EPS 추세

06

매출$87M

2016-12-31 → 2025-12-31

EPS$-1.28

2016-12-31 → 2025-12-31

잉여현금흐름$5M

2018-12-31 → 2025-12-31

순이익률-11.9%

2016-12-31 → 2025-12-31

가치 평가 및 비율 07–12

가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?

지표	HBIO	5년 평균	동종업계 중앙값	결론
P/E (TTM)	-5.65년 평균 ≈-21.7	≈-21.7	·	·
P/S (TTM)	0.45년 평균 ≈1.4	≈1.4	·	·
P/B (MRQ)	5.15년 평균 ≈2.4	≈2.4	·	·
EV / EBITDA	-1.35년 평균 ≈51.1	≈51.1	·	·
주가 / FCF (TTM)	-33.95년 평균 ≈802.1	≈802.1	·	·
주가 / 현금 흐름 (TTM)	58.35년 평균 ≈83.3	≈83.3	·	·
EV / Revenue (EV / 매출)	0.75년 평균 ≈1.7	≈1.7	·	·
EV / FCF	11.85년 평균 ≈900.4	≈900.4	·	·
주가 / 유형 장부 가치 (MRQ)	31.7	·	·	·

동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.

수익성 총, 영업 및 순이익률; ROE, ROA, ROIC

지표	HBIO	5년 평균	동종업계 중앙값	결론
매출 총이익률 (TTM)	58.2%5년 평균 ≈57.1%	≈57.1%	·	·
영업이익률 (TTM)	-0.28%5년 평균 ≈-13.1%	≈-13.1%	-46.3%	최상위권
EBITDA Margin (EBITDA 마진)	-56.1%5년 평균 ≈-13.1%	≈-13.1%	-46.3%	최상위권
세전 마진 (TTM)	-12.0%5년 평균 ≈-17.8%	≈-17.8%	-90.8%	최상위권
순이익률 (TTM)	-11.9%5년 평균 ≈-18.1%	≈-18.1%	-89.7%	최상위권
ROA (TTM)	-13.3%5년 평균 ≈-14.6%	≈-14.6%	-42.4%	약함
ROE (TTM)	-89.9%5년 평균 ≈-84.5%	≈-84.5%	-78.9%	약함
ROIC	-96.8%5년 평균 ≈-20.8%	≈-20.8%	-83.1%	약함

재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성

지표	HBIO	5년 평균	동종업계 중앙값	결론
부채 / 자기자본 비율 (MRQ)	4.95년 평균 ≈1.0	≈1.0	·	·
유동비율 (MRQ)	1.95년 평균 ≈1.9	≈1.9	2.5	낮은 유동성
Quick Ratio (당좌 비율)	1.15년 평균 ≈0.9	≈0.9	0.9	낮은 유동성
장기 부채 / 자기 자본 (MRQ)	4.95년 평균 ≈0.8	≈0.8	·	·

성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR

지표	HBIO	5년 평균	동종업계 중앙값	결론
Revenue YoY (매출 YoY)	-8.1%5년 평균 ≈-2.7%	≈-2.7%	·	·
Revenue CAGR 3Y (매출 CAGR 3년)	-8.6%5년 평균 ≈-4.3%	≈-4.3%	·	·
Revenue CAGR 5Y (매출 CAGR 5년)	-3.2%	·	·	·

주당 지표 EPS, 주당 순자산, 주당 현금 흐름, 주당 배당금

지표	HBIO	5년 평균	동종업계 중앙값	결론
EPS (Diluted) (EPS (희석))	$-1.285년 평균 ≈$-0.47	≈$-0.47	·	·
Revenue / Share (주당 매출)	$1.955년 평균 ≈$2.49	≈$2.49	·	·
Cash Flow / Share (주당 현금 흐름)	$0.155년 평균 ≈$0.11	≈$0.11	·	·
Cash / Share (주당 현금)	$0.195년 평균 ≈$0.14	≈$0.14	·	·

자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율

지표	HBIO	5년 평균	동종업계 중앙값	결론
Asset Turnover (자산 회전율)	0.85년 평균 ≈0.8	≈0.8	0.4	최상위권
Inventory Turnover (재고 회전율)	1.75년 평균 ≈1.8	≈1.8	·	·
Receivables Turnover (매출 채권 회전율)	5.65년 평균 ≈6.1	≈6.1	5.7	약함
Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.)	≈$273.9K	·	·	·

가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가

실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일

14

평균 서프라이즈 -18.3%

다음 실적 11월 04, 2026

기간	보고서	EPS Actual	EPS 예상	서프라이즈
2026년 6월 30일	8월 11, 2026	$-0.14	$-0.21	34.6%
2026년 3월 31일	5월 12, 2026	$-0.77	$-0.63	-21.8%
2025년 12월 31일		$0.00	$0.36	-100.0%
2025년 9월 30일		$0.00	$0.05	-100.0%
2025년 6월 30일		$-0.10	$-0.10	2.0%
2025년 3월 31일		$-0.10	$-0.41	75.5%

전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름

15

손익계산서 17

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue	$87M	$94M	$112M	$113M	$119M	$102M	$116M	$121M	$77M	$105M	$109M	$109M
Cost of Revenue	$37M	$39M	$46M	$53M	$51M	$44M	$52M	$58M	$38M	$56M	$60M	$59M
Gross Profit	$50M	$55M	$66M	$61M	$68M	$58M	$64M	$63M	$39M	$48M	$49M	$49M
R&D Expense	$9M	$10M	$12M	$12M	$11M	$9M	$11M	$11M	$6M	$5M	$6M	$5M
SG&A Expense	$18M	$21M	$23M	$24M	$24M	$24M	$23M	$21M	$18M	$21M	$20M	$17M
Operating Expenses	$98M	$61M	$64M	$68M	$66M	$58M	$64M	$62M	$40M	$51M	$50M	$43M
Operating Income	$-49M	$-6M	$2M	$-7M	$2M	$221.0K	$377.0K	$984.0K	$-635.0K	$-3M	$-2M	$7M
Interest Expense	·	·	·	·	·	·	·	$5M	$713.0K	$639.0K	$846.0K	$990.0K
Other Non-op	$-3M	$-325.0K	$-227.0K	$302.0K	$-666.0K	$-806.0K	$-469.0K	$-4M	$-739.0K	$-179.0K	$-1M	$-1M
Pretax Income	$-57M	$-12M	$-3M	$-9M	$-140.0K	$-7M	$-6M	$-8M	$-3M	$-3M	$-4M	$4M
Income Tax	$-686.0K	$740.0K	$859.0K	$337.0K	$148.0K	$518.0K	$-815.0K	$-4M	$-605.0K	$1M	$15M	$2M
Net Income	$-57M	$-12M	$-3M	$-10M	$-288.0K	$-8M	$-5M	$-3M	$-865.0K	$-4M	$-19M	$2M
EPS (Basic)	$-1.28	$-0.28	$-0.08	$-0.23	$-0.01	·	$-0.12	$-0.08	$-0.02	$-0.13	$-0.57	$0.07
EPS (Diluted)	$-1.28	$-0.28	$-0.08	$-0.23	·	·	$-0.12	$-0.08	$-0.02	$-0.13	$-0.57	$0.07
Shares (Basic)	44,391,000	43,538,000	42,420,000	41,413,000	40,343,000	38,640,000	37,813,580	36,453,126	34,753,325	34,211,521	33,592,775	32,170,683
Shares (Diluted)	44,391,000	43,538,000	42,420,000	41,413,000	40,343,000	38,640,000	37,813,580	36,453,126	34,753,325	34,211,521	33,592,775	33,236,569
EBITDA	$-49M	$-6M	$2M	$-7M	$2M	$221.0K	$377.0K	$984.0K	$-101.0K	$-3M	$-2M	·

대차대조표 28

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	$9M	$4M	$4M	$5M	$8M	$8M	$8M	$8M	$6M	$6M	$7M	$14M
Receivables	$16M	$15M	$16M	$17M	$22M	$18M	$21M	$21M	$13M	$16M	$18M	$16M
Inventory	$21M	$23M	$25M	$26M	$28M	$22M	$22M	$25M	$17M	$20M	$22M	$21M
Other Current Assets	$3M	$3M	$4M	$3M	$4M	$3M	$2M	$3M	$4M	$4M	$4M	$5M
Current Assets	$48M	$45M	$49M	$51M	$62M	$52M	$54M	$58M	$48M	$45M	$51M	$57M
PP&E (Net)	$5M	$5M	$4M	$3M	$3M	$4M	$5M	$6M	$4M	$4M	$6M	$5M
PP&E (Gross)	$23M	$21M	$18M	$18M	$18M	$21M	$20M	$23M	$19M	$19M	$22M	$20M
Accum. Depreciation	$18M	$16M	$14M	$15M	$14M	$17M	$15M	$17M	$16M	$15M	$16M	$15M
Goodwill	$10M	$56M	$57M	$56M	$58M	$59M	$57M	$57M	$36M	$38M	$40M	$40M
Intangibles	$8M	$11M	$16M	$21M	$27M	$33M	$38M	$46M	$10M	$17M	$21M	$21M
Other Non-current Assets	$3M	$3M	$6M	$8M	$5M	$1M	$2M	$2M	$324.0K	$128.0K	$152.0K	$380.0K
Total Assets	$80M	$127M	$137M	$145M	$162M	$156M	$165M	$169M	$109M	$108M	$120M	$136M
Accounts Payable	$4M	$5M	$6M	$6M	$5M	$6M	$5M	$7M	$4M	$6M	$9M	$6M
Accrued Liabilities	·	·	·	·	·	·	$6M	$7M	$4M	$5M	$4M	$4M
Current Liabilities	$22M	$55M	$27M	$23M	$25M	$21M	$25M	$25M	$14M	$15M	$19M	$18M
Capital Leases	$7M	$6M	$5M	$5M	$6M	$7M	$8M	·	·	·	·	·
Deferred Tax	$317.0K	$710.0K	$776.0K	$590.0K	$2M	$2M	$2M	$2M	$3M	$6M	$4M	$1M
Other Non-current Liabilities	$1M	$1M	$1M	$1M	$486.0K	$3M	$749.0K	$3M	·	·	·	·
Total Liabilities	$66M	$63M	$64M	$73M	$79M	$80M	$83M	$86M	$28M	$36M	$42M	$40M
Long-term Debt	$36M	$37M	$37M	$47M	$48M	$48M	$54M	$61M	$12M	$14M	$19M	$21M
Total Debt	$36M	$37M	$37M	$47M	$49M	$48M	$50M	$59M	$9M	$11M	$16M	·
Common Stock	$447.0K	$441.0K	$434.0K	$454.0K	$452.0K	$444.0K	$438.0K	$436.0K	$419.0K	$418.0K	$416.0K	$397.0K
Retained Earnings	$-215M	$-158M	$-146M	$-142M	$-133M	$-132M	$-125M	$-120M	$-117M	$-116M	$-112M	$-93M
Treasury Stock	·	·	·	·	$0	$11M	·	·	·	·	·	·
AOCI	$-12M	$-16M	$-14M	$-15M	$-10M	$-13M	$-13M	$-14M	$-11M	$-17M	$-12M	$-8M
Stockholders' Equity	$14M	$63M	$73M	$72M	$83M	$77M	$82M	$83M	$81M	$72M	$78M	$95M
Liabilities + Equity	$80M	$127M	$137M	$145M	$162M	$156M	$165M	$169M	$109M	$108M	$120M	$136M
Shares Outstanding	4,471,989	44,074,475	43,394,509	42,081,707	41,142,876	39,407,080	38,188,208	37,378,802	35,018,478	35,018,478	33,979,265	32,563,256

현금 흐름 16

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Stock-based Comp	$2M	$4M	$5M	$4M	$4M	$4M	$3M	$3M	$4M	$3M	$3M	$2M
Deferred Tax	$-553.0K	$310.0K	$228.0K	$-498.0K	$-371.0K	$-143.0K	$-398.0K	$-4M	$-2M	$-279.0K	$15M	$1M
Amort. of Intangibles	$4M	$5M	$6M	$6M	$6M	$6M	$6M	$5M	$2M	$3M	$3M	$3M
Restructuring	$200.0K	$800.0K	$391.0K	$2M	$1M	$2M	$1M	·	$0	$-4.0K	$788.0K	$1M
Operating Cash Flow	$7M	$1M	$14M	$1M	$1M	$9M	$8M	$3M	$1M	$5M	$705.0K	$4M
CapEx	$1M	$3M	$2M	$2M	$1M	$1M	$1M	$986.0K	$890.0K	·	·	·
Investing Cash Flow	$-2M	$-1M	$-2M	$-2M	$-1M	$-1M	$-229.0K	$-54M	$-917.0K	$-62.0K	$-8M	$-14M
Debt Issued	$40M	$0	·	·	·	·	·	·	·	·	·	·
Net Debt Issued	$15M	$-6M	$-4M	$-3M	$-4M	$-67M	$-12M	$-20M	$-5M	$-9M	$-8M	·
Stock Issued	·	·	·	·	·	·	·	$5M	$160.0K	$182.0K	$2M	$2M
Net Stock Activity	·	·	·	·	·	·	·	$5M	$160.0K	$182.0K	$2M	·
Financing Cash Flow	$-1M	$-131.0K	$-12M	$-3M	$-252.0K	$-8M	$-8M	$53M	$-2M	$-5M	$-540.0K	$-1M
Net Change in Cash	$5M	$-175.0K	$-225.0K	$-3M	$-496.0K	$-18.0K	$162.0K	$2M	$137.0K	$-1M	$-7M	$-12M
Taxes Paid	$-98.0K	$-159.0K	$207.0K	$534.0K	$577.0K	$416.0K	$374.0K	$98.0K	$13.0K	·	·	·
Free Cash Flow	$5M	$-1M	$12M	$-438.0K	$67.0K	$8M	$7M	$2M	·	·	·	·
Levered FCF	·	·	·	·	·	·	·	$-995.1K	·	·	·	·

수익성 8

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Gross Margin	57.7%	58.2%	58.9%	53.7%	56.9%	56.9%	55.4%	52.3%	46.7%	46.3%	44.8%	·
Operating Margin	-56.1%	-6.6%	1.7%	-6.1%	1.7%	0.22%	0.32%	0.81%	-0.10%	-2.9%	-1.6%	·
Net Margin	-65.5%	-13.2%	-3.0%	-8.4%	-0.24%	-7.6%	-4.0%	-2.4%	-0.85%	-4.1%	-17.5%	·
Pretax Margin	-66.3%	-12.4%	-2.3%	-8.1%	-0.12%	-7.1%	-4.7%	-6.6%	-2.1%	-2.9%	-3.3%	·
EBITDA Margin	-56.1%	-6.6%	1.7%	-6.1%	1.7%	0.22%	0.32%	0.81%	-0.10%	-2.9%	-1.6%	·
ROA	-54.9%	-9.4%	-2.4%	-6.2%	-0.18%	-4.9%	-2.8%	-2.1%	-0.80%	-3.8%	-14.9%	·
ROE	-384.8%	-19.3%	-4.6%	-13.2%	-0.36%	-10.2%	-5.9%	-3.6%	-1.1%	-5.8%	-22.0%	·
ROIC	-96.8%	-6.6%	2.3%	-6.0%	3.2%	0.19%	0.24%	0.37%	-0.05%	-5.0%	-9.6%	·

유동성 및 지급능력 5

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Current Ratio	2.2	0.8	1.8	2.2	2.4	2.5	2.1	2.7	3.4	3.1	2.6	·
Quick Ratio	1.1	0.3	0.8	0.9	1.2	1.2	1.1	1.4	1.6	1.5	1.3	·
Debt / Equity	2.6	0.6	0.5	0.7	0.6	0.6	0.6	0.7	0.1	0.2	0.2	·
LT Debt / Equity	2.6	0.0	0.4	0.6	0.5	0.6	0.6	0.7	0.1	0.2	0.2	·
Interest Coverage	·	·	·	·	·	·	·	0.2	-0.1	-4.7	-2.0	·

효율성 3

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Asset Turnover	0.8	0.7	0.8	0.7	0.7	0.6	0.7	0.9	0.9	0.9	0.8	·
Inventory Turnover	1.7	1.6	1.8	1.9	2.1	2.0	2.2	2.7	2.6	2.7	2.8	·
Receivables Turnover	5.6	6.1	6.8	5.9	6.0	5.3	5.5	6.9	6.4	6.3	6.5	·

주당 5

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Book Value / Share	$0.31	$1.44	$1.68	$1.72	$2.03	$1.95	$2.14	$2.21	$2.31	$2.10	$2.28	·
Revenue / Share	$1.95	$2.16	$2.65	$2.74	$2.95	$2.64	$3.07	$3.31	$2.93	$3.06	$3.23	·
Cash Flow / Share	$0.15	$0.03	$0.33	$0.03	$0.03	$0.24	$0.21	$0.08	$0.03	$0.16	$0.02	·
Cash / Share	$0.19	$0.09	$0.10	$0.11	$0.19	$0.21	$0.22	$0.22	$0.16	$0.16	$0.20	·
EPS (TTM)	$-1.28	$-0.28	$-0.08	$-0.23	·	$-0.21	$-0.12	$-0.08	$-0.02	$-0.13	$-0.57	$0.07

성장률 3

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue YoY	-8.1%	-16.1%	-0.96%	-4.7%	16.5%	·	·	·	·	·	·	·
Revenue CAGR 3Y	-8.6%	-7.5%	3.2%	·	·	·	·	·	·	·	·	·
Revenue CAGR 5Y	-3.2%	·	·	·	·	·	·	·	·	·	·	·

가치 평가 (TTM) 13

지표	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Revenue TTM	$87M	$94M	$112M	$113M	$119M	$102M	$116M	$121M	$77M	$105M	$109M	$109M
Net Income TTM	$-57M	$-12M	$-3M	$-10M	$-288.0K	$-8M	$-5M	$-3M	$-865.0K	$-4M	$-19M	$2M
Market Cap	$30M	$93M	$232M	$117M	$290M	$169M	$116M	$119M	$116M	$105M	$118M	·
Enterprise Value	$57M	$126M	$265M	$159M	$331M	$209M	$158M	$169M	$119M	$111M	$128M	·
P/E	-0.5	-7.5	-66.9	-12.0	·	-20.4	-25.4	-39.8	-165.0	-23.5	-6.1	81.0
P/S	0.3	1.0	2.1	1.0	2.4	1.7	1.0	1.0	1.5	1.0	1.1	·
P/B	2.2	1.5	3.2	1.6	3.5	2.2	1.4	1.4	1.4	1.5	1.5	·
P / Cash Flow	4.5	64.6	16.5	101.2	229.8	18.1	14.5	41.2	109.3	19.5	167.2	·
P / FCF	5.5	-77.2	19.0	-266.1	4329.2	20.7	17.1	62.6	·	·	·	·
EV / EBITDA	-1.2	-20.3	139.8	-23.0	160.1	945.8	419.8	172.2	-1176.3	-37.0	-74.5	·
EV / FCF	10.5	-104.8	21.6	-363.4	4938.0	25.6	23.2	89.3	·	·	·	·
EV / Revenue	0.7	1.3	2.4	1.4	2.8	2.0	1.4	1.4	1.5	1.1	1.2	·
Earnings Yield	-191.0%	-13.3%	-1.5%	-8.3%	·	-4.9%	-3.9%	-2.5%	-0.61%	-4.3%	-16.4%	1.2%

손익계산서 16

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue	$23M	$21M	$24M	$21M	$20M	$22M	$25M	$22M	$23M	$25M	$28M	$25M	$29M	$30M	$28M	$27M
Cost of Revenue	$10M	$9M	$10M	$9M	$9M	$10M	$11M	$9M	$10M	$10M	$12M	$11M	$12M	$12M	$13M	$15M
Gross Profit	$13M	$12M	$14M	$12M	$12M	$12M	$14M	$13M	$13M	$15M	$16M	$15M	$17M	$18M	$16M	$12M
R&D Expense	$2M	$2M	$2M	$2M	$2M	$2M	$2M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M	$3M
SG&A Expense	$5M	$5M	$4M	$4M	$4M	$5M	$5M	$5M	$6M	$6M	$5M	$6M	$5M	$6M	$6M	$6M
Operating Expenses	$14M	$13M	$12M	$12M	$12M	$62M	$14M	$15M	$15M	$17M	$16M	$16M	$16M	$17M	$16M	$16M
Operating Income	$-978.0K	$-1M	$2M	$197.0K	$-819.0K	$-50M	$11.0K	$-2M	$-2M	$-2M	$282.0K	$-933.0K	$796.0K	$2M	$-457.0K	$-4M
Other Non-op	$-125.0K	$-405.0K	$-1M	$-365.0K	$-434.0K	$-193.0K	$516.0K	$-518.0K	$-181.0K	$-142.0K	$-332.0K	$45.0K	$-372.0K	$432.0K	$465.0K	$-179.0K
Pretax Income	$-3M	$-3M	$-3M	$-1M	$-2M	$-51M	$590.0K	$-4M	$-3M	$-4M	$-1M	$-562.0K	$-2M	$1M	$-892.0K	$-5M
Income Tax	$14.0K	$117.0K	$-357.0K	$97.0K	$28.0K	$-454.0K	$572.0K	$311.0K	$-353.0K	$210.0K	$715.0K	$677.0K	$-1M	$585.0K	$774.0K	$-1M
Net Income	$-3M	$-3M	$-3M	$-1M	$-2M	$-50M	$18.0K	$-5M	$-3M	$-5M	$-2M	$-1M	$-980.0K	$622.0K	$-2M	$-3M
EPS (Basic)	$-0.64	$-0.77	$-0.06	$-0.03	$-0.52	$-11.42	$0.01	$-0.11	$-0.07	$-0.11	$-0.04	$-0.03	$-0.02	$0.01	$-0.04	$-0.08
EPS (Diluted)	$-0.64	$-0.77	$-0.06	$-0.03	$-0.52	$-11.42	$0.01	$-0.11	$-0.07	$-0.11	$-0.04	$-0.03	$-0.02	$0.01	$-0.04	$-0.08
Shares (Basic)	4,526,000	4,473,000	·	44,556,000	4,430,000	4,410,000	·	43,614,000	43,486,000	43,402,000	·	42,688,000	42,354,000	42,119,000	·	41,637,000
Shares (Diluted)	4,526,000	4,473,000	·	44,556,000	4,430,000	4,410,000	·	43,614,000	43,486,000	43,402,000	·	42,688,000	42,354,000	42,783,000	·	41,637,000
EBITDA	$-978.0K	$-1M	·	$197.0K	$-819.0K	$-50M	·	$-2M	$-2M	$-2M	·	$-933.0K	$796.0K	$2M	·	$-4M

대차대조표 26

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Cash & Equivalents	$7M	$7M	$9M	$7M	$7M	$6M	$4M	$5M	$4M	$4M	$4M	$5M	$4M	$4M	$5M	$5M
Receivables	$14M	$15M	$16M	$12M	$12M	$13M	$15M	$13M	$12M	$15M	$16M	$15M	$17M	$18M	$17M	$15M
Inventory	$22M	$22M	$21M	$22M	$22M	$23M	$23M	$26M	$25M	$24M	$25M	$26M	$26M	$27M	$26M	$26M
Other Current Assets	$3M	$4M	$3M	$3M	$3M	$3M	$3M	$3M	$5M	$4M	$4M	$4M	$5M	$4M	$3M	$6M
Current Assets	$46M	$47M	$48M	$44M	$45M	$45M	$45M	$47M	$46M	$48M	$49M	$50M	$53M	$52M	$51M	$52M
PP&E (Net)	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$5M	$4M	$4M	$3M	$3M	$3M	$3M	$4M
PP&E (Gross)	·	·	$23M	·	·	·	$21M	·	·	·	$18M	·	·	·	$18M	·
Accum. Depreciation	·	·	$18M	·	·	·	$16M	·	·	·	$14M	·	·	·	$15M	·
Goodwill	$9M	$9M	$10M	$10M	$10M	$9M	$56M	$57M	$57M	$57M	$57M	$56M	$57M	$57M	$56M	$55M
Intangibles	$6M	$7M	$8M	$8M	$9M	$10M	$11M	$12M	$13M	$15M	$16M	$17M	$18M	$20M	$21M	$22M
Other Non-current Assets	$3M	$3M	$3M	$4M	$4M	$4M	$3M	$3M	$3M	$5M	$6M	$8M	$6M	$8M	$8M	$8M
Total Assets	$76M	$78M	$80M	$78M	$80M	$80M	$127M	$131M	$129M	$133M	$137M	$140M	$143M	$146M	$145M	$147M
Accounts Payable	$6M	$5M	$4M	$5M	$5M	$5M	$5M	$5M	$6M	$6M	$6M	$6M	$5M	$6M	$6M	$6M
Current Liabilities	$25M	$24M	$22M	$54M	$55M	$56M	$55M	$23M	$23M	$26M	$27M	$24M	$23M	$23M	$23M	$21M
Capital Leases	$6M	$6M	$7M	$7M	$7M	$7M	$6M	$7M	$5M	$5M	$5M	$4M	$5M	$5M	$5M	$6M
Deferred Tax	$311.0K	$313.0K	$317.0K	$733.0K	$734.0K	$717.0K	$710.0K	$707.0K	$764.0K	$772.0K	$776.0K	$661.0K	$667.0K	$546.0K	$590.0K	$1M
Other Non-current Liabilities	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$2M	$2M	$1M	$1M	$892.0K	$1M	$1M	$1M	$420.0K
Total Liabilities	$69M	$68M	$66M	$64M	$64M	$65M	$63M	$66M	$62M	$64M	$64M	$65M	$68M	$71M	$73M	$75M
Long-term Debt	$37M	$36M	$36M	$34M	$35M	$36M	$37M	$38M	$36M	$36M	$37M	$39M	$41M	$44M	$47M	$49M
Total Debt	$37M	$36M	·	·	·	·	·	$38M	$36M	$36M	·	$39M	$42M	$44M	·	$50M
Common Stock	$447.0K	$447.0K	$447.0K	$446.0K	$445.0K	$442.0K	$441.0K	$436.0K	$436.0K	$434.0K	$434.0K	$457.0K	$457.0K	$455.0K	$454.0K	$453.0K
Retained Earnings	$-221M	$-218M	$-215M	$-212M	$-211M	$-208M	$-158M	$-158M	$-153M	$-150M	$-146M	$-144M	$-143M	$-142M	$-142M	$-141M
AOCI	$-12M	$-12M	$-12M	$-12M	$-12M	$-14M	$-16M	$-13M	$-15M	$-15M	$-14M	$-15M	$-14M	$-15M	$-15M	$-16M
Stockholders' Equity	$7M	$10M	$14M	$14M	$16M	$15M	$63M	$65M	$67M	$69M	$73M	$74M	$75M	$74M	$72M	$72M
Liabilities + Equity	$76M	$78M	$80M	$78M	$80M	$80M	$127M	$131M	$129M	$133M	$137M	$140M	$143M	$146M	$145M	$147M
Shares Outstanding	4,552,305	4,510,182	44,719,894	44,579,665	44,531,198	44,213,746	44,074,475	43,616,621	43,610,883	43,421,251	43,394,509	42,688,246	42,688,246	42,190,043	42,081,707	41,657,688

현금 흐름 11

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Stock-based Comp	$380.0K	$257.0K	$459.0K	$324.0K	$472.0K	$600.0K	$961.0K	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M
Amort. of Intangibles	$820.0K	$820.0K	$850.0K	$855.0K	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$1M	$2M	$2M
Restructuring	$318.0K	$235.0K	$29.0K	$48.0K	$30.0K	$93.0K	$225.0K	$179.0K	$396.0K	$0	·	·	·	·	$485.0K	$1M
Operating Cash Flow	$325.0K	$-662.0K	$-96.0K	$1M	$3M	$3M	$2M	$-842.0K	$-846.0K	$1M	$4M	$4M	$4M	$2M	$3M	$649.0K
CapEx	$688.0K	$426.0K	$449.0K	$207.0K	$89.0K	$513.0K	$301.0K	$880.0K	$818.0K	$645.0K	$830.0K	$217.0K	$517.0K	$224.0K	$235.0K	$442.0K
Investing Cash Flow	$-916.0K	$-620.0K	$-599.0K	$-348.0K	$-233.0K	$-683.0K	$-466.0K	$-1M	$458.0K	$-225.0K	$-1M	$-401.0K	$-625.0K	$288.0K	$-235.0K	$-442.0K
Net Debt Issued	·	$0	·	·	·	$-1M	·	·	·	$-3M	·	·	·	$-2M	·	·
Financing Cash Flow	$-38.0K	$-9.0K	$2M	$-1M	$-1M	$-1M	$-1M	$2M	$177.0K	$-1M	$-4M	$-3M	$-2M	$-3M	$-3M	$377.0K
Net Change in Cash	$-595.0K	$-2M	$2M	$-625.0K	$2M	$1M	$-461.0K	$521.0K	$-207.0K	$-28.0K	$-1M	$1M	$535.0K	$-719.0K	$-636.0K	$885.0K
Taxes Paid	$-164.0K	$-5.0K	$-144.0K	$-2.0K	$46.0K	$2.0K	$-474.0K	$184.0K	$105.0K	$26.0K	$39.0K	$53.0K	$249.0K	$-134.0K	$41.0K	$141.0K
Free Cash Flow	·	$-1M	·	·	·	$2M	·	·	·	$758.0K	·	·	·	$2M	·	·

수익성 8

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Gross Margin	55.6%	59.0%	·	58.4%	56.4%	56.0%	·	58.1%	57.2%	60.3%	·	58.1%	58.0%	61.2%	·	45.2%
Operating Margin	-4.3%	-5.7%	·	0.96%	-4.0%	-228.1%	·	-8.5%	-9.0%	-9.3%	·	-3.7%	2.8%	5.8%	·	-14.0%
Net Margin	-12.8%	-16.5%	·	-6.0%	-11.2%	-231.2%	·	-21.9%	-12.7%	-19.1%	·	-4.9%	-3.4%	2.1%	·	-12.7%
Pretax Margin	-12.7%	-15.9%	·	-5.5%	-11.0%	-233.3%	·	-20.4%	-14.2%	-18.3%	·	-2.2%	-7.3%	4.0%	·	-17.4%
EBITDA Margin	-4.3%	-5.7%	·	0.96%	-4.0%	-228.1%	·	-8.5%	-9.0%	-9.3%	·	-3.7%	2.8%	5.8%	·	-14.0%
ROA	-3.7%	-4.3%	·	-1.2%	-2.2%	-47.3%	·	-3.5%	-2.1%	-3.4%	·	-0.86%	-0.66%	0.41%	·	-2.3%
ROE	-25.1%	-27.5%	·	-3.1%	-5.5%	-120.4%	·	-6.9%	-4.1%	-6.6%	·	-1.7%	-1.3%	0.83%	·	-4.6%
ROIC	-2.2%	-2.6%	·	1.5%	-5.3%	-331.8%	·	-1.9%	-1.8%	-2.3%	·	-1.8%	0.32%	0.76%	·	-2.2%

유동성 및 지급능력 4

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Current Ratio	1.9	2.0	·	0.8	0.8	0.8	·	2.1	2.1	1.9	·	2.1	2.3	2.3	·	2.4
Quick Ratio	0.8	0.9	·	0.3	0.4	0.3	·	0.8	0.7	0.8	·	0.8	0.9	0.9	·	0.9
Debt / Equity	4.9	3.6	·	·	·	·	·	0.6	0.5	0.5	·	0.5	0.6	0.6	·	0.7
LT Debt / Equity	4.9	3.6	·	·	·	·	·	0.5	0.5	0.5	·	0.5	0.5	0.6	·	0.6

효율성 3

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Asset Turnover	0.3	0.3	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2	0.2	0.2	·	0.2
Inventory Turnover	0.5	0.4	·	0.4	0.4	0.4	·	0.4	0.4	0.4	·	0.4	0.4	0.4	·	0.6
Receivables Turnover	1.7	1.5	·	1.7	1.7	1.5	·	1.6	1.6	1.5	·	1.7	1.7	1.6	·	1.6

주당 5

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Book Value / Share	$1.63	$2.23	·	$0.32	$0.35	$0.34	·	$1.50	$1.54	$1.58	·	$1.74	$1.77	$1.76	·	$1.73
Revenue / Share	$5.02	$4.64	·	$0.46	$0.46	$0.49	·	$0.50	$0.53	$0.56	·	$0.59	$0.68	$0.70	·	$0.65
Cash Flow / Share	·	$-0.15	·	·	·	$0.07	·	·	·	$0.03	·	·	·	$0.04	·	·
Cash / Share	$1.43	$1.57	·	$0.15	$0.17	$0.13	·	$0.10	$0.09	$0.10	·	$0.13	$0.10	$0.09	·	$0.12
EPS (TTM)	$-1.50	$-1.38	·	$-11.96	$-12.04	$-11.59	·	$-0.33	$-0.25	$-0.20	·	$-0.08	$-0.13	$-0.05	·	·

가치 평가 (TTM) 11

지표	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Revenue TTM	$88M	$86M	·	$87M	$89M	$91M	·	$98M	$101M	$107M	·	$113M	$114M	$115M	·	$118M
Net Income TTM	$-10M	$-10M	·	$-54M	$-57M	$-58M	·	$-14M	$-11M	$-9M	·	$-3M	$-5M	$-2M	·	$-7M
Market Cap	$28M	$22M	·	$20M	$20M	$25M	·	$117M	$124M	$184M	·	$184M	$234M	$177M	·	$107M
Enterprise Value	$58M	$51M	·	·	·	·	·	$151M	$156M	$216M	·	$217M	$272M	$218M	·	$151M
P/E	-4.1	-3.5	·	-0.0	-0.0	-0.0	·	-8.2	-11.4	-21.2	·	-53.8	-42.2	-84.0	·	·
P/S	0.3	0.3	·	0.2	0.2	0.3	·	1.2	1.2	1.7	·	1.6	2.1	1.5	·	0.9
P/B	3.8	2.2	·	1.4	1.2	1.7	·	1.8	1.8	2.7	·	2.5	3.1	2.4	·	1.5
P / Tangible Book	·	·	·	·	·	·	·	·	·	·	·	189.4	897.9	·	·	·
P / Cash Flow	·	-33.2	·	·	·	8.4	·	·	·	131.2	·	·	·	97.8	·	·
EV / Revenue	0.7	0.6	·	·	·	·	·	1.5	1.5	2.0	·	1.9	2.4	1.9	·	1.3
Earnings Yield	-24.4%	-28.3%	·	-2718.2%	-2736.4%	-2033.3%	·	-12.3%	-8.8%	-4.7%	·	-1.9%	-2.4%	-1.2%	·	·

최신 기간은 왼쪽에 · null 값은 ·로 표시

재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년

16

지표	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
매출	$87M	$94M	$112M	$113M	$119M
매출 총이익률 %	57.7%	58.2%	58.9%	53.7%	56.9%
영업이익률 %	-56.1%	-6.6%	1.7%	-6.1%	1.7%
순이익	$-57M	$-12M	$-3M	$-10M	$-288.0K
희석 EPS	$-1.28	$-0.28	$-0.08	$-0.23	·

지표	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
부채 / 자기자본 비율	2.6	0.6	0.5	0.7	0.6
유동비율	2.2	0.8	1.8	2.2	2.4
당좌 비율	1.1	0.3	0.8	0.9	1.2

지표	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
잉여현금흐름	$5M	$-1M	$12M	$-438.0K	$67.0K

기관 투자자 (13F) 8개의 제출자 · $5.7M 전체 · 기준일 2026년 6월 30일

17

분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.

보유자 8

보유 가치 $5.7M

신규 포지션 0

청산 포지션 0

기관 활동 — Q2 2026 대 이전 분기

신규 포지션	청산 포지션	증가함	감소	순주식 변동
0 (0 이전 분기 대비)	0 (-57 이전 분기 대비)	2 (+2 이전 분기 대비)	0 (-3 이전 분기 대비)	+90K

Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.

기관	가치	주식	% 추적된 13F 중	유형
AMH Equity Ltd	$1,774,844	4,047,535	31.32%	주식
VANGUARD GROUP INC	$1,286,671	1,923,275	22.71%	주식
Meros Investment Management, LP	$1,125,401	182,992	19.86%	주식
NANO CAP NEW MILLENNIUM GROWTH FUND L P	$879,954	143,082	15.53%	주식
TWO SIGMA ADVISERS, LP	$587,578	878,556	10.37%	주식
Point72 Asia (Singapore) Pte. Ltd.	$6,445	14,697	0.11%	주식
WOLVERINE TRADING, LLC	$5,102	11,600	0.09%	콜 옵션
Financial Connections Group, Inc.	$0	30	0.00%	주식

행동주의자 및 5% 이상 소유자 5 보유

18

SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.

제출자	제출됨	지분	상태	목적	제출
BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider	2026년 3월 23일	15.97%	최초 제출	·	SEC
ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 제출 서류	2020년 6월 22일	·	최초 제출	·	SEC
HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 제출 서류	2008년 5월 20일	·	최초 제출	·	SEC
	2007년 12월 14일	·	최초 제출	·	SEC
미공개 보고자	2002년 7월 29일	·	최초 제출	M&A / 매각	SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

회사 내부자 34 명의 내부자 · 14 임원 · 18 이사

19

내부자	역할	마지막 활동	보유 주식 수	매수 12개월	순매수/매도 12개월
John D Duke	Chief Executive Officer	2026년 3월 20일 A	180,000	1	$25,050
Jeffrey Duchemin	Chief Executive Officer	2019년 7월 7일 D	464,528	0	$0
Mark T Frost	Chief Financial Officer	2026년 3월 20일 A	47,500	1	$25,000
Jennifer Cote	Chief Financial Officer	2025년 3월 19일 F	159,019	0	$0
Michael A. Rossi	Chief Financial Officer	2022년 12월 29일 F	260,540	0	$0
Kamalam Unninayar	Chief Financial Officer	2019년 3월 7일 A	73,858	0	$0
Bryce Anthony Chicoyne	Chief Financial Officer	2007년 5월 1일 A	·	0	$0
Mark A Norige	President, Harvard Apparatus	2007년 5월 1일 A	·	0	$0
David L Strack	President of Subsidiary	2005년 5월 25일 A	·	0	$0
Kenneth Fletcher Olson	Chief Operating Officer	2021년 12월 29일 F	155,595	0	$0
Yash Singh	Executive Vice President	2019년 10월 31일 A	39,286	0	$0
Yong Sun	VP - Commercial Operations	2019년 1월 1일 F	242,805	0	$0
Yoav Sibony	VP - Global Sales	2015년 8월 3일 A	21,582	0	$0
Paul Bailey	VP, Finance & Admin.	2005년 5월 25일 A	·	0	$0
Seth Benjamin Benson	이사	2026년 6월 9일 A	27,556	0	$0
Katherine A. Eade	이사	2026년 6월 9일 A	58,669	0	$0
Robert E. Gagnon	이사	2026년 6월 9일 A	27,556	0	$0
William Snider	이사	2026년 6월 9일 A	48,556	2	$103,604
Stephen J Denelsky	이사	2026년 6월 9일 A	37,556	1	$48,700
James W Green	이사	2025년 8월 15일 D	2,452,566	0	$0
Thomas W Loewald	이사	2024년 5월 21일 A	295,311	0	$0
Bertrand Loy	이사	2024년 5월 21일 A	56,575	0	$0
Alan I Edrick	이사	2024년 5월 21일 A	273,911	0	$0
John F Kennedy	이사	2021년 3월 23일 G	323,344	0	$0
Susan M. Steele	이사	2021년 1월 4일 A	49,400	0	$0
George Uveges	이사	2018년 3월 12일 M	142,685	0	$0
Earl R Lewis	이사	2018년 1월 2일 A	477,050	0	$0
David Green	이사	2017년 2월 7일 S	925,571	0	$0
Neal J Harte	이사	2016년 5월 25일 M	106,399	0	$0
Robert A Dishman	이사	2015년 4월 28일 A	51,055	0	$0
Chane Graziano	10% 소유주	2013년 11월 7일 G	3,005,150	0	$0
HSO LIMITED PARTNERSHIP	10% 소유주	2008년 5월 16일 S	2,757,257	0	$0
Thomas Mcnaughton	·	2013년 11월 1일 J	171,613	0	$0
Susan M Luscinski	·	2013년 11월 1일 J	469,720	0	$0

SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당

ETF 보유 현황 2 ETF 보유

20

가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.

펀드	비중	단위	기준일	출처
VXF · VANGUARD INDEX FUNDS	0.00%	42,043 SH	2026년 8월 19일	일간
VTI · VANGUARD INDEX FUNDS	0.00%	123,470 SH	2026년 8월 19일	일간

HBIO 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력

21

평점 · 8 명의 애널리스트 매수

중앙값 목표 $7.50 -10.1%

2 25.0% 적극 매수

4 50.0% 매수

2 25.0% 보유

0 0.0% 매도

0 0.0% 적극 매도

12개월 목표 주가

1 명의 애널리스트 · 2026-10-04

평균 목표 $7.50 -10.1%

저가$7.50 평균$7.50 고가$7.50

동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업

22

회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.

티커	시가총액	P/E	매출 YoY	순이익률	ROE	매출 총이익률
HBIO	$30M	-0.5	-8.1%	-65.5%	-384.8%	57.7%
HYFT	·	·	·	-89.7%	-78.9%	58.8%
CIRC	·	·	·	·	·	·
RPID	·	-2.8	19.7%	-140.3%	-107.4%	·
BNGO	$16M	-0.3	-7.4%	-92.6%	-58.8%	·
TMO	$257.86B	32.7	3.9%	15.0%	13.0%	·

나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목

26

중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.

선택 항목이 저장되어 모든 티커에서 유지됩니다.

HBIO Harvard Bioscience, Inc. - Common Stock

HBIO 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위

HBIO 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의

Harvard Bioscience, Inc. - Common Stock 정보 위키백과 회사 개요

History

Products

Finance

10년 성과 매출, 순이익, 마진 및 EPS 추세

가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?

수익성 총, 영업 및 순이익률; ROE, ROA, ROIC

재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성

성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR

주당 지표 EPS, 주당 순자산, 주당 현금 흐름, 주당 배당금

자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율

실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일

전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름

재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년

기관 투자자 (13F) 8개의 제출자 · $5.7M 전체 · 기준일 2026년 6월 30일

행동주의자 및 5% 이상 소유자 5 보유

회사 내부자 34 명의 내부자 · 14 임원 · 18 이사

ETF 보유 현황 2 ETF 보유

HBIO 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력

12개월 목표 주가

동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업

나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목